NCT04261790View on ClinicalTrials.gov

Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis

PHASE4CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 1, 2020

Primary Completion Date

October 31, 2024

Study Completion Date

November 1, 2024

Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
DRUG

Ocrelizumab

Patients will be treated with two courses of ocrelizumab (Ocrevus) 600mg/course, for one year and then will stop the medication and will be monitored for the return of the disease activity. Those who experience the return of the disease activity can go back on the medication.

Trial Locations (1)

21287

Johns Hopkins University, Baltimore

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Johns Hopkins University

OTHER